Original Source(s)
Related Content
FDA Approves Less Frequent Lebrikizumab Dosing
Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.
June 10, 2026
-
2 min
AI Tool May Cut Macular Edema Referrals
An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.
June 18, 2026
-
4 min